Pazopanib: An Antiangiogenic Drug in Perspective

• Shibuya M : Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis.BMB Rep.41(4), 278–286 (2008).
   PubMed Web of Science ®Google Scholar
• Khosravi Shahi P , Fernández PinedaI: Tumoral angiogenesis: review of the literature.Cancer Invest.26(1), 104–108 (2008).
   PubMed Web of Science ®Google Scholar
• Erman M : Molecular mechanisms of signal transduction: epidermal growth factor receptor family, vascular endothelial growth factor family, Kit, platelet-derived growth factor receptor, Ras.J. BUON12(Suppl. 1), S83–S94 (2007).
   PubMedGoogle Scholar
• Shibuya M : Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis.J. Biochem. Mol. Biol.39(5), 469–478 (2006).
   PubMedGoogle Scholar
• Hurwitz H , FehrenbacherL, NovotnyWet al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.N. Engl. J. Med.350(23), 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Sandler A , GrayR, PerryMCet al.: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.N. Engl. J. Med.355(24), 2542–2550 (2006).
   PubMed Web of Science ®Google Scholar
• Miller K , WangM, GralowJet al.: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.N. Engl. J. Med.357(26), 2666–2676 (2007).
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ , DesjardinsA, HerndonJE2ndet al.: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.J. Clin. Oncol.25(30), 4722–4729 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , HutsonTE, TomczakPet al.: Sunitinib versus interferon α in metastatic renal-cell carcinoma.N. Engl. J. Med.356(2), 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , HutsonTE, TomczakPet al.: Overall survival and updated results for sunitinib compared with interferon a in patients with metastatic renal cell carcinoma.J. Clin. Oncol.27(22), 3584–3590 (2009).
   PubMed Web of Science ®Google Scholar
• Escudier B , EisenT, StadlerWMet al.: Sorafenib in advanced clear-cell renal-cell carcinoma.N. Engl. J. Med.356(2), 125–134 (2007).
   PubMed Web of Science ®Google Scholar
• Escudier B , EisenT, StadlerWMet al.: Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trial.J. Clin. Oncol.27(20), 3312–3318 (2009).
   PubMed Web of Science ®Google Scholar
• Llovet JM , RicciS, MazzaferroVet al.: Sorafenib in advanced hepatocellular carcinoma.N. Engl. J. Med.359(4), 378–390 (2008).
   PubMed Web of Science ®Google Scholar
• Kumar R , KnickVB, RudolphSKet al.: Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity.Mol. Cancer Ther.6(7), 2012–2021 (2007).
   PubMed Web of Science ®Google Scholar
• Harris PA , BoloorA, CheungMet al.: Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-m ethyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.J. Med. Chem.51(15), 4632–4640 (2008).
   PubMed Web of Science ®Google Scholar
• Sonpavde G , HutsonTE: Pazopanib: a novel multitargeted tyrosine kinase inhibitor.Curr. Oncol. Rep.9(2), 115–119 (2007).
   PubMedGoogle Scholar
• Sloan B , ScheinfeldNS: Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy.Curr. Opin. Investig. Drugs9(12), 1324–1335 (2008).
   PubMed Web of Science ®Google Scholar
• Podar K , AndersonKC: Inhibition of VEGF signaling pathways in multiple myeloma and other malignancies.Cell Cycle6(5), 538–542 (2007).
   PubMed Web of Science ®Google Scholar
• Podar K , TononG, SattlerMet al.: The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma.Proc. Natl Acad. Sci. USA103(51), 19478–19483 (2006).
   PubMed Web of Science ®Google Scholar
• Podar K , SimonciniM, Le GouillSet al.: Effects of the indazolylpyrimidine GW786034 on angiogenesis and MM cell growth: therapeutic implications.Blood104(11), 2452 (2004).
   PubMed Web of Science ®Google Scholar
• Suttle AB , HurwitzH, DowlatiA: Pharmacokinetics (PK) and tolerability of GW-786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumors.J. Clin. Oncol.22(Suppl. 14), 3054 (2004).
   Web of Science ®Google Scholar
• Hurwitz H , DowlatiA, SavageS: Safety, tolerability and pharmacokinetics of oral administration of GW-786034 in pts with solid tumors.J. Clin. Oncol.23(Suppl. 16), 3012 (2005).
   Web of Science ®Google Scholar
• Hurwitz HI , DowlatiA, SainiSet al.: Phase I trial of pazopanib in patients with advanced cancer.Clin. Cancer Res.15(12), 4220–4227 (2009).
   PubMed Web of Science ®Google Scholar
• Yau CC , ChenPJ, CurtisCMet al.: A Phase I study of pazopanib in patients with advanced hepatocellular carcinoma.J. Clin. Oncol.27, 3561 (2009) (ASCO meeting abstract).
   Google Scholar
• Dejonge M , SavageS, VerweijJ: A Phase I, open-label study of the safety and pharmacokinetics (PK) of pazopanib (P) and lapatinib (L) administered concurrently.J. Clin. Oncol.24(18), 3088 (2006).
   Web of Science ®Google Scholar
• Frentzas SN , GrovesMD, BarriusoJet al.: Pazopanib and lapatinib in patients with relapsed malignant glioma: results of a Phase I/II study.J. Clin. Oncol.27(Suppl. 15), 2040 (2009).
   Web of Science ®Google Scholar
• Suttle B , JonesS, DowlatiA: Phase I study of the safety and pharmacokinetics (PK) of paclitaxel or paclitaxel with carboplatin administered in combination with pazopanib (GW-786034).J. Clin. Oncol.25(18), 14118 (2007).
   Web of Science ®Google Scholar
• Altorki N , GuarinoM, LeeP: Preoperative treatment with pazopanib (GW-786034), a multikinase angiogenesis inhibitor in early-stage non-small cell lung cancer (NSCLC): a proof-of-concept Phase II study.J. Clin. Oncol.44, 7557 (2008).
   Google Scholar
• Altorki N , HeymachJV, GuarinoM: Phase II study of pazopanib (GW-786034) given preoperatively in stage I-II non-small cell lung cancer (NSCLC): a proof-of-concept study.Ann. Oncol.19(8), 2250 (2008).
   Google Scholar
• Schoenleber SJ , KurtzDM, TalwalkarJAet al.: Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis.Br. J. Cancer100(9), 1385–1392 (2009).
   PubMed Web of Science ®Google Scholar
• Yang ZF , PoonRT: Vascular changes in hepatocellular carcinoma.Anat. Rec. (Hoboken)291(6), 721–734 (2008).
   PubMedGoogle Scholar
• Machein M , de MiguelLS: Angiogenesis in gliomas.Recent Results Cancer Res.171, 193–215 (2009).
   PubMedGoogle Scholar
• Idbaih A , DucrayF, Sierra Del RioM, Hoang-XuanK, DelattreJY: Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors.Oncologist13(9), 978–992 (2008).
   PubMed Web of Science ®Google Scholar
• Saltz LB , ClarkeS, Díaz-RubioEet al.: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III study.J. Clin. Oncol.26(12), 2013–2019 (2008).
   PubMed Web of Science ®Google Scholar
• Saltz LB : Second- and third-line treatment options for unresectable metastatic colorectal cancer.Gastrointest. Cancer Res.2(6), 299–302 (2008).
   PubMedGoogle Scholar
• Hochster HS , HartLL, RamanathanRKet al.: Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.J. Clin. Oncol.26(21), 3523–3529 (2008).
   PubMed Web of Science ®Google Scholar
• Brady J , MiddletonM, MidgleyRSet al.: A Phase I study of pazopanib in combination with FOLFOX 6 or capeOx in subjects with colorectal cancer.J. Clin. Oncol.27, 4133 (2009) (ASCO meeting abstract).
   Web of Science ®Google Scholar
• Turner HE , HarrisAL, MelmedS, WassJA: Angiogenesis in endocrine tumors.Endocr. Rev.24(5), 600–632 (2003).
   PubMed Web of Science ®Google Scholar
• Bible KC , SmallridgeRC, MaplesWJet al.: Phase II trial of pazopanib in progressive, metastatic, iodine-insensitive differentiated thyroid cancers.J. Clin. Oncol.27, 3521 (2009) (ASCO meeting abstract).
   Web of Science ®Google Scholar
• Reinmuth N , LierschR, RaedelMet al.: Combined anti-PDGFRα and PDGFRβ targeting in non-small cell lung cancer.Int. J. Cancer124(7), 1535–1544 (2009).
   PubMed Web of Science ®Google Scholar
• Bremnes RM , CampsC, SireraR: Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood.Lung Cancer51(2), 143–158 (2006).
   PubMed Web of Science ®Google Scholar
• Gutierrez M , GiacconeG: Antiangiogenic therapy in nonsmall cell lung cancer.Curr. Opin. Oncol.20(2), 176–182 (2008).
   PubMed Web of Science ®Google Scholar
• Taylor SK , ChiaS, DentSet al.: A Phase II study of GW786034 (pazopanib) in patients with recurrent or metastatic invasive breast carcinoma: results after completion of stage I: a trial of the Princess Margaret Hospital Phase II Consortium.J. Clin. Oncol.27, 1133 (2009) (ASCO meeting abstract).
   Web of Science ®Google Scholar
• Brown MR , BlanchetteJO, KohnEC: Angiogenesis in ovarian cancer.Baillieres Best Pract. Res. Clin. Obstet. Gynaecol.14(6), 901–918 (2000).
   PubMed Web of Science ®Google Scholar
• Spannuth WA , SoodAK, ColemanRL: Angiogenesis as a strategic target for ovarian cancer therapy.Nat. Clin. Pract. Oncol.5(4), 194–204 (2008).
   PubMedGoogle Scholar
• Friedlander M , HancockKC, BenignoB: Pazopanib (GW-786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: initial results of a Phase II study.J. Clin. Oncol.25(18), 5561 (2007).
   Web of Science ®Google Scholar
• Friedlander M , HancockKC, BenignoB: Pazopanib (GW-786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: results of a Phase II study.Ann. Oncol.19(8), 6630 (2008).
   Google Scholar
• Kovacs MJ , ReeceDE, MarcellusDet al.: A Phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma – NCIC CTG IND.145.Invest. New Drugs24(6), 529–535 (2006).
   PubMed Web of Science ®Google Scholar
• Zangari M , AnaissieE, StopeckAet al.: Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.Clin. Cancer Res.10(1 Pt 1), 88–95 (2004).
   PubMed Web of Science ®Google Scholar
• Prince HM , HönemannD, SpencerAet al.: Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a Phase 2 study of pazopanib (GW786034).Blood113(19), 4819–4820 (2009).
   PubMed Web of Science ®Google Scholar
• Potti A , GantiAK, FosterHet al.: Immunohistochemical detection of HER-2/neu, c-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas.Anticancer Res.24(1), 333–337 (2004).
   PubMed Web of Science ®Google Scholar
• Potti A , GantiAK, TendulkarKet al.: Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma.J. Cancer Res. Clin. Oncol.130(1), 52–56 (2004).
   PubMed Web of Science ®Google Scholar
• Yudoh K , KanamoriM, OhmoriK, YasudaT, AokiM, KimuraT: Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas.Br. J. Cancer84(12), 1610–1615 (2001).
   PubMed Web of Science ®Google Scholar
• Hayes AJ , Mostyn-JonesA, KobanMU, A’HernR, BurtonP, ThomasJM: Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma.Br. J. Surg.91(2), 242–247 (2004).
   PubMed Web of Science ®Google Scholar
• Sleijfer S , PapaiZ, Le CesneA: Phase II study of pazopanib (GW-786034) in patients (pts) with relapsed or refractory soft tissue sarcoma (STS): EORTC 62043.J. Clin. Oncol.25(18), 10031 (2007).
   Google Scholar
• Sleijfer S , Ray-CoquardI, PapaiZet al.: Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a Phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).J. Clin. Oncol.27(19), 3126–3132 (2009).
   PubMed Web of Science ®Google Scholar
• Sleijfer S , Ray-CoquardI, PapaiZ: Pazopanib (GW-786034) in patients (pts) with relapsed or refractory soft tissue sarcoma (STS); a Phase II study from the EORTC STBSG (EORTC 62043).Ann. Oncol.19(8), 8680 (2008).
   Google Scholar
• Keohan ML , MorganJA, D’AdamoDR: Continuous daily dosing (CDD) of sunitinib (SU) in patients with metastatic soft tissue sarcomas (STS) other than GIST: results of a Phase II trial.J. Clin. Oncol.26, 10533 (2008) (ASCO meeting abstract).
   Google Scholar
• Vigil CE , ChiapporiAA, WilliamsCAet al.: Phase II study of sunitinib malate (SM) in subjects with metastatic and/or surgically unresectable non-GIST soft tissue sarcomas.J. Clin. Oncol.26, 10535 (2008) (ASCO meeting abstract).
   Web of Science ®Google Scholar
• Casali PG , StacchiottiS, PalassiniEet al.: Evaluation of the antitumor activity of sunitinib malate (SM) in solitary fibrous tumor (SFT).J. Clin. Oncol.27(15s) (2009) (Abstract 10.71).
   Google Scholar
• Ryan CW , von MehrenM, RankinCJet al.: Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505.J. Clin. Oncol.26(Suppl.), 10532 (2008) (ASCO meeting abstract).
   Google Scholar
• Maki RG , KeohanML, UndeviaSDet al.: Updated results of a Phase II study of oral multi-kinase inhibitor sorafenib in sarcomas, CTEP study #7060.J. Clin. Oncol.26, 10531 (2008).
   Web of Science ®Google Scholar
• Kim WY , KaelinWG: Role of VHL gene mutation in human cancer.J. Clin. Oncol.22(24), 4991–5004 (2004).
   PubMed Web of Science ®Google Scholar
• Takahashi A , SasakiH, KimSJet al.: Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis.Cancer Res.54(15), 4233–4237 (1994).
   PubMed Web of Science ®Google Scholar
• Rini BI : Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.Clin. Cancer Res.13(4), 1098–1106 (2007).
   PubMed Web of Science ®Google Scholar
• Hutson TE , FiglinRA: Renal cell cancer.Cancer J.13(5), 282–286 (2007).
   PubMed Web of Science ®Google Scholar
• Hutson TE , DavisID, MachielsJP: Predictive and prognostic factors in Phase II renal cell carcinoma trial with pazopanib (GW-786034), a multi-kinase angiogenesis inhibitor.Ann. Oncol.19(8), 5780 (2008).
   Google Scholar
• Sonpavde G , HutsonTE, SternbergCN: Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.Expert Opin. Investig. Drugs17(2), 253–261 (2008).
   PubMed Web of Science ®Google Scholar
• Hutson TE , DavisID, MachielsJP: Pazopanib (GW-786034) is active in metastatic renal cell carcinoma (RCC): interim results of a Phase II randomized discontinuation trial (RDT).J. Clin. Oncol.25(18), 5031 (2007).
   Google Scholar
• Gasparini G , ToiM, GionMet al.: Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma.J. Natl Cancer Inst.89(2), 139–147 (1997).
   PubMedGoogle Scholar
• Marty M , PivotX: The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.Eur. J. Cancer44(7), 912–920 (2008).
   PubMed Web of Science ®Google Scholar
• Blackwell KL , DewhirstMW, LiotchevaVet al.: HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors.Clin. Cancer Res.10(12 Pt 1), 4083–4088 (2004).
   PubMed Web of Science ®Google Scholar
• Pegram MD , ReeseDM: Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor.Semin. Oncol.29(3 Suppl. 11), 29–37 (2002).
   PubMed Web of Science ®Google Scholar
• Slamon DGH , KabbinavarFF, AmitO, RichieM, PanditeL, GoodmanV: Randomized study of pazopanib + lapatinib vs lapatinib alone in patients with HER-2-positive advanced or metastatic breast cancer.J. Clin. Oncol.26, 1016 (2008).
   PubMed Web of Science ®Google Scholar
• Slamon DGH , AmitO: Pazopanib + lapatinib is more active than lapatinib alone: Updated results from a randomized study in patients with ErbB2-positive advanced or metastatic breast cancer.Ann. Oncol.19(8), P139 (2008).
   Google Scholar
• Rasila KK , BurgerRA, SmithH, LeeFC, VerschraegenC: Angiogenesis in gynecological oncology – mechanism of tumor progression and therapeutic targets.Int. J. Gynecol. Cancer15(5), 710–726 (2005).
   PubMed Web of Science ®Google Scholar
• Frumovitz M , SoodAK: Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies.Gynecol. Oncol.104(3), 768–778 (2007).
   PubMed Web of Science ®Google Scholar
• Monk B , MasL, ZarbaJJet?al.: A randomized Phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L+P) in advanced and recurrent cervical cancer (CC).J. Clin. Oncol.27, 5520 (2009).
   Web of Science ®Google Scholar
• Sternberg CN , SzczylikC, LeeEet al.: A randomized, double-blind Phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC).J. Clin. Oncol.27(Suppl. 15), 5021 (2009).
   Web of Science ®Google Scholar
• Hawkins RE , HongSJ, UlysAet al.: An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma (RCC) in ASCO.J. Clin. Oncol.27, 5520 (2009).
   Web of Science ®Google Scholar
• Chen HX , CleckJN: Antiangiogenic clinical strategies: adverse effects of anticancer agents that target the VEGF pathway.Nat. Rev. Clin. Oncol.6(8), 465–477 (2009).
   PubMed Web of Science ®Google Scholar
• Hutson TE , FiglinRA, KuhnJG, MotzerRJ: Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.Oncologist13(10), 1084–1096 (2008).
   PubMed Web of Science ®Google Scholar
• Hutson TE : Targeted therapy for renal cell carcinoma: a new treatment paradigm.Proc. Bayl. Univ. Med. Cent.20(3), 244–248 (2007).
   PubMedGoogle Scholar
• Taylor SK , ChiaS, DentS: A Phase II study of GW786034 (pazopanib) in patients with recurrent or metastatic invasive breast carcinoma: Results after completion of stage I: a trial of the Princess Margaret Hospital Phase II Consortium.J. Clin. Oncol.27, 1133 (2009) (ASCO meeting abstract).
   Web of Science ®Google Scholar

Website

• Clinicaltrials.gov: Pazopanib in Treating Patients With Metastatic Soft Tissue Sarcoma That Has Relapsed or Not Responded to Treatment http://clinicaltrials.gov/ct2/show/NCT00794521
   Google Scholar